How does brigatinib work?

Brigatinib, as an oral targeted therapy drug for non-small cell lung cancer (NSCLC), its principle of action mainly revolves around inhibiting the activity of ALK (anaplastic lymphoma kinase) tyrosine kinase.

In ALKpositive NSCLC, there is ALK fusion gene, which leads to abnormal activation of the protein, thereby promoting the growth and spread of tumor cells. Brigatinib can specifically bind to these abnormal ALK fusion proteins, inhibit their activation, and thereby block the signaling pathway. This highly specific mode of action allows brigatinib to accurately attack tumor cells and reduce damage to normal cells.

By inhibiting the activity ofALKtyrosine kinase, brigatinib can significantly inhibit the growth and spread of tumor cells and induce tumor cell apoptosis. This process has been fully verified in clinical trials. Among patients treated with brigatinib, up to 83% of patients experienced tumor shrinkage, and some patients even achieved complete remission.

In addition to directly inhibiting tumor growth, brigatinib can also reduce tumor progression and recurrence. It can delay the progression of the disease and reduce the recurrence and metastasis rates of lung cancer by continuously inhibiting the ALK signaling pathway. This characteristic makes brigatinib play an important role in the treatment of lung cancer.

Brigatinib is designed to have less impact on normal cells and is therefore clinically well tolerated. Compared with traditional chemotherapy drugs, brigatinib has fewer side effects and can significantly improve patients' quality of life.

In summary, brigatinib exerts a powerful anti-tumor effect by specifically inhibiting the activity of ALK tyrosine kinase. It not only directly inhibits the growth and spread of tumor cells, but also reduces tumor progression and recurrence while maintaining good safety and tolerability.

References:

https://en.wikipedia.org/wiki/Brigatinib